Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Penelope MacRae

Set Alert for Articles By Penelope MacRae

Latest From Penelope MacRae

Cadila Healthcare Merges Four Subsidiaries

India’s Cadila Healthcare, which has been suffering on the earnings front, is amalgamating four subsidiaries under its roof to reduce overheads from managing separate entities and avoid duplication of efforts after posting weak second-quarter earnings.

Business Strategies Strategy

Sun Fights US Charges Over Delays

Sun Pharmaceutical Industries is back before US courts as it contests US antitrust charges filed by plaintiffs over the delayed market entry of generic versions of three major drugs.

Legal Issues Launches

Ajanta Beats Q2 Expectations

India’s Ajanta has reported a 7% drop in second-quarter net profit with its African branded generics remaining a problem area. However, US sales climbed by nearly 40% and analysts remain positive on the company’s outlook, buoyed by a beat on revenue estimates.

Sales & Earnings Strategy

Mochida Debuts Japanese Teriparatide Biosimilar

Mochida has launched the first Japanese teriparatide biosimilar rival to Eli Lilly’s blockbuster osteoporosis drug Forteo. The company is hoping for big sales for the injectable in the country where the government is aiming to rein in healthcare costs for its rapidly ageing population.

Biosimilars Launches

Cipla Rumored Frontrunner For Wockhardt Deal

Cipla is reportedly leading the pack to acquire business divisions of debt-laden Wockhardt in a transaction that could be worth hundreds of millions of dollars and would boost the Mumbai-based company’s domestic presence.

Deals Strategy

AAM Slams USMCA Over Mexico Biologics Impact

Biologic exclusivity provisions in the proposed USMCA US-Mexico-Canada trade agreement will not create a new market for original biologics in Mexico, as firms have been selling them in the country since before 2001, the US Association for Accessible Medicines has argued in response to brand industry claims.

Trade Biosimilars
See All